Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 02, 2023

Interim PET–Guided Treatment for Early-Stage NLPHL

Blood

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Blood 2023 May 31;[EPub Ahead of Print], DA Eichenauer, I Bühnen, C Baues, C Kobe, H Kaul, R Greil, AA Moccia, JM Zijlstra, B Hertenstein, MS Topp, M Just, B von Tresckow, HT Eich, M Fuchs, M Dietlein, S Hartmann, A Engert, P Borchmann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading